JPRN-UMIN000026161已完成未知
Sodium glucose cotransporter inhibitor 2, Tofogliflozin versus glimepiride, comparative trial in Patients with type 2 diabetes On Body composition (STOP-OB study) - Sodium glucose cotransporter inhibitor 2, Tofogliflozin versus glimepiride, comparative trial in Patients with type 2 diabetes On Body composition (STOP-OB study)
Japan society for Patient Reported Outcome0 个研究点目标入组 64 人开始时间: 2017年2月16日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who fall into any of the following criteria are excluded from participating in the study. 1. Patients with type 1 diabetes or secondary diabetes 2. Patients who have used antidiabetic medication other than DPP-4 inhibitors or metformin (e.g. insulin, GLP-1 receptor agonist) within the 12 weeks until consenting 3. Patients who have changed the dosage of a diuretic agent or started a new diuretic agent within the 12 weeks until consenting 4. Patients with BMI below 18.5 kg/m2 or BMI 35 kg/m2 or higher at the time of consenting 5. Patients with conditions contraindicated the use of study drugs 6. Patients with a medical history of hypersensitivity to the study drugs 7. Patients with moderate to severe renal function impairment, or at the terminal stage of renal failure (eGFR< 60mL/min/1.73m2) 8. Patients with severe hepatic impairment 9. Patients with a medical history of stroke or cerebral infarction 10. Patients who are currently or possibly pregnant, breastfeeding or planning to be pregnant 11. Patients with moderate to severe heart failure (New York Heart Association [NYHA] functional class III or higher) 12. Patients with urinary tract infection or genital infection 13. Patients currently with a malignancy, or with a medical history of a malignancy (excluding those who are not currently treated for the malignancy or show no redevelopment of it, or a physician assures no relapse during the study period) 14. Patients with other conditions that investigators/physicians think inappropriate to join the study
研究者
相似试验
进行中（未招募）
1 期
A comparison of two drugs for treating patients with Chronic Kidney Disease and protein in the urineChronic Kidney Disease with albuminuriaMedDRA version: 23.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.0Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2022-000740-29-DKDepartment of Renal Medicine, Aarhus University Hospital20
招募中
1 期
SOdium-Glucose cotransporter 2 inhibitor, ALDosterone AntagonIst, or both for heart failure with Preserved Ejection Fraction: a two-centre randomised three-treatment three-period crossover trialHeart Failure with Preserved Ejection FractionMedDRA version: 20.1Level: LLTClassification code 10076396Term: Heart failure with preserved ejection fractionSystem Organ Class: 100000004849EUCTR2020-000973-26-PTFaculdade de Medicina da Universidade do Porto108
招募中
3 期
Empagliflozin in stage 4 non-diabetic kidney diseaseChronic kidney diseaseACTRN12622001371785niversity of Otago6
已完成
不适用
The Sodium glucose transporter 2 inhibitor with acute insulin treatment for controlling severe hyperglycemia in patients with type 2 Diabetes mellitustype2 diabetes mellitusJPRN-UMIN000018997Toho University School of Medicine,Divsion of diabetes, metabolism and endocrinology20
招募中
1 期
Study of the effects of sodium-glucose cotransporter 2 inhibitors on kidney function in patients undergoing cardiac surgeryEUCTR2022-002453-25-NLAmsterdam UMC784